Cargando…

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen

Selective phosphoinositide 3-kinase (PI3K)/AKT/mTOR inhibitors are currently under evaluation in clinical studies. To identify tumor types that are sensitive to PI3K pathway inhibitors we screened compounds targeting PI3Kα/δ (AZD8835), PI3Kβ/δ (AZD8186), AKT (AZD5363) and mTORC1/2 (AZD2014) against...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lynch, James T., McEwen, Robert, Crafter, Claire, McDermott, Ultan, Garnett, Mathew J., Barry, Simon T., Davies, Barry R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008349/ https://www.ncbi.nlm.nih.gov/pubmed/26989080 http://dx.doi.org/10.18632/oncotarget.8031

Ejemplares similares

The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response()
por: Garnett, Mathew J, et al.
Publicado: (2014)

High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer
por: Williams, Steven P., et al.
Publicado: (2017)

Corrigendum: High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer
por: Williams, Steven P., et al.
Publicado: (2018)

Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties
por: Menden, Michael P., et al.
Publicado: (2013)

Targeting the RB-E2F pathway in breast cancer
por: Johnson, Jackie, et al.
Publicado: (2016)

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
por: Dunn, Shanade, et al.
Publicado: (2022)

Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
por: Sanchez, Vanessa Edna, et al.
Publicado: (2019)

The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment
por: El Zawily, Amr, et al.
Publicado: (2017)

The germline genetic component of drug sensitivity in cancer cell lines
por: Menden, Michael P., et al.
Publicado: (2018)

PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia
por: Silveira, André Bortolini, et al.
Publicado: (2015)

TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia
por: Thielemans, Naomi, et al.
Publicado: (2022)

Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy
por: Knijnenburg, Theo A., et al.
Publicado: (2016)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

PTEN/PI3K/Akt pathway alters sensitivity of T-cell acute lymphoblastic leukemia to l-asparaginase
por: Hlozkova, Katerina, et al.
Publicado: (2022)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

Translating evidence-based guidelines into practice: a survey of practices of commissioners and managers of the English stop smoking services
por: McDermott, Máirtín S, et al.
Publicado: (2012)

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity
por: Carnevalli, Larissa S., et al.
Publicado: (2018)

FANCD2 limits replication stress and genome instability in cells lacking BRCA2
por: Michl, Johanna, et al.
Publicado: (2016)

Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia
por: Lim, Fang Qi, et al.
Publicado: (2022)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia
por: Vega-Garcia, Nerea, et al.
Publicado: (2020)

Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
por: Alameen, Ayman A.M., et al.
Publicado: (2016)

Activation of PI3K Is Indispensable for Interleukin 7–mediated Viability, Proliferation, Glucose Use, and Growth of T Cell Acute Lymphoblastic Leukemia Cells
por: Barata, Joao T., et al.
Publicado: (2004)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs
por: McDermott, Niamh, et al.
Publicado: (2017)

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia
por: Canté-Barrett, K, et al.
Publicado: (2016)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells
por: Naderali, Elahe, et al.
Publicado: (2019)

PB1753: SYNERGISTIC ANTITUMOR EFFECT OF CHIDAMIDE WITH VENETOCLAX IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY SUPPRESSING PI3K/AKT SIGNALING
por: Song, D., et al.
Publicado: (2022)

Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines
por: Anjam-Najmedini, Ali, et al.
Publicado: (2022)

Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia
por: Tan, Shi Hao, et al.
Publicado: (2017)

CYTOLOGIC STUDIES ON RHEUMATIC FEVER : I. THE CHARACTERISTIC CELL OF THE RHEUMATIC GRANULOMA
por: McEwen, Currier
Publicado: (1932)

A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia
por: Cavalcante, Marcio de Souza, et al.
Publicado: (2016)

IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias
por: Gusscott, Samuel, et al.
Publicado: (2016)

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells
por: Holz, Clemens, et al.
Publicado: (2023)

Aberrant splicing in B-cell acute lymphoblastic leukemia
por: Black, Kathryn L, et al.
Publicado: (2018)

Aberrant splicing in B-cell acute lymphoblastic leukemia
por: Black, Kathryn L, et al.
Publicado: (2019)

Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways
por: Yang, Tingfang, et al.
Publicado: (2016)

GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways
por: Ye, Wei, et al.
Publicado: (2016)

Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics
por: Schwab, Claire, et al.
Publicado: (2018)

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
por: Wang, Xiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_olofjg88frgi9musgc1uipqb7c